相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
Andrew J. Clark et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Elizabeth Pham et al.
CLINICAL CANCER RESEARCH (2015)
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2014)
High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
John D. Hainsworth et al.
CLINICAL GENITOURINARY CANCER (2013)
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2013)
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
Scott Eliasof et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Annamaria Rapisarda et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802
Naomi B. Haas et al.
MEDICAL ONCOLOGY (2012)
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivaani Kummar et al.
CLINICAL CANCER RESEARCH (2011)
Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents
Jessica Jie Wei Lou et al.
PLOS ONE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
A Rapisarda et al.
CANCER RESEARCH (2004)
A phase II study of irinotecan in patients with advanced renal cell carcinoma
K Fizazi et al.
CANCER (2003)
The genetic basis of cancer of the kidney
WM Linehan et al.
JOURNAL OF UROLOGY (2003)
分享论文
